Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Large Decline in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 38,100 shares, a decline of 51.0% from the October 31st total of 77,800 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.9% of the company’s shares are short sold.

Bio-Path Stock Performance

NASDAQ:BPTH traded down $0.03 on Thursday, hitting $0.77. 61,635 shares of the stock were exchanged, compared to its average volume of 1,102,472. Bio-Path has a 52 week low of $0.61 and a 52 week high of $12.37. The company’s 50-day moving average price is $0.95 and its 200 day moving average price is $1.47.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Bio-Path in a research report on Sunday. They issued a “sell” rating on the stock.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Hedge funds and other institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.